Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland.

BACKGROUND: Substance use disorder treatment and recovery support services are critical for achieving and maintaining recovery. There are limited data on how structural and social changes due to the COVID-19 pandemic impacted individual-level experiences with substance use disorder treatment-related services among community-based samples of people who inject drugs. METHODS: People with a recent history of injection drug use who were enrolled in the community-based AIDS Linked to the IntraVenous Experience study in Baltimore, Maryland participated in a one-time, semi-structured interview between July 2021 and February 2022 about their experiences living through the COVID-19 pandemic (n = 28). An iterative inductive coding process was used to identify themes describing how structural and social changes due to the COVID-19 pandemic affected participants' experiences with substance use disorder treatment-related services. RESULTS: The median age of participants was 54 years (range = 24-73); 10 (36%) participants were female, 16 (57%) were non-Hispanic Black, and 8 (29%) were living with HIV. We identified several structural and social changes due the pandemic that acted as barriers and facilitators to individual-level engagement in treatment with medications for opioid use disorder (MOUD) and recovery support services (e.g., support group meetings). New take-home methadone flexibility policies temporarily facilitated engagement in MOUD treatment, but other pre-existing rigid policies and practices (e.g., zero-tolerance) were counteracting barriers. Changes in the illicit drug market were both a facilitator and barrier to MOUD treatment. Decreased availability and pandemic-related adaptations to in-person services were a barrier to recovery support services. While telehealth expansion facilitated engagement in recovery support group meetings for some participants, other participants faced digital and technological barriers. These changes in service provision also led to diminished perceived quality of both virtual and in-person recovery support group meetings. However, a facilitator of recovery support was increased accessibility of individual service providers (e.g., counselors and Sponsors). CONCLUSIONS: Structural and social changes across several socioecological levels created new barriers and facilitators of individual-level engagement in substance use disorder treatment-related services. Multilevel interventions are needed to improve access to and engagement in high-quality substance use disorder treatment and recovery support services among people who inject drugs.

Valproic Acid-Associated Hyperammonemia: A Systematic Review.

BACKGROUND: Hyperammonemia is an adverse effect that poses clinical uncertainty around valproic acid (VPA) use. The prevalence of symptomatic and asymptomatic hyperammonemia and its relationship to VPA concentration is not well established. There is also no clear guidance regarding its management. This results in variability in the monitoring and treatment of VPA-induced hyperammonemia. To inform clinical practice, this systematic review aims to summarize evidence available around VPA-associated hyperammonemia and its prevalence, clinical outcomes, and management. METHODS: An electronic search was performed through Ovid MEDLINE, Ovid Embase, Web of Science, and PsycINFO using search terms that identified hyperammonemia in patients receiving VPA. Two reviewers independently performed primary title and abstract screening with a third reviewer resolving conflicting screening results. This process was repeated during the full-text review process. RESULTS: A total of 240 articles were included. Prevalence of asymptomatic hyperammonemia (5%-73%) was higher than symptomatic hyperammonemia (0.7%-22.2%) and occurred within the therapeutic range of VPA serum concentration. Various risk factors were identified, including concomitant medications, liver injury, and defects in carnitine metabolism. With VPA discontinued, most symptomatic patients returned to baseline mental status with normalized ammonia level. There was insufficient data to support routine monitoring of ammonia level for VPA-associated hyperammonemia. CONCLUSIONS: Valproic acid-associated hyperammonemia is a common adverse effect that may occur within therapeutic range of VPA. Further studies are required to determine the benefit of routine ammonia level monitoring and to guide the management of VPA-associated hyperammonemia.

Dynamic data-enabled stratified sampling for trial invitations with application in NHS-Galleri.

BACKGROUND: Participants of health research studies such as cancer screening trials usually have better health than the target population. Data-enabled recruitment strategies might be used to help minimise healthy volunteer effects on study power and improve equity. METHODS: A computer algorithm was developed to help target trial invitations. It assumes participants are recruited from distinct sites (such as different physical locations or periods in time) that are served by clusters (such as general practitioners in England, or geographical areas), and the population may be split into defined groups (such as age and sex bands). The problem is to decide the number of people to invite from each group, such that all recruitment slots are filled, healthy volunteer effects are accounted for, and equity is achieved through representation in sufficient numbers of all major societal and ethnic groups. A linear programme was formulated for this problem. RESULTS: The optimisation problem was solved dynamically for invitations to the NHS-Galleri trial (ISRCTN91431511). This multi-cancer screening trial aimed to recruit 140,000 participants from areas in England over 10 months. Public data sources were used for objective function weights, and constraints. Invitations were sent by sampling according to lists generated by the algorithm. To help achieve equity the algorithm tilts the invitation sampling distribution towards groups that are less likely to join. To mitigate healthy volunteer effects, it requires a minimum expected event rate of the primary outcome in the trial. CONCLUSION: Our invitation algorithm is a novel data-enabled approach to recruitment that is designed to address healthy volunteer effects and inequity in health research studies. It could be adapted for use in other trials or research studies.

Interruptions to HIV Care Delivery During Pandemics and Natural Disasters: A Qualitative Study of Challenges and Opportunities From Frontline Healthcare Providers in Western Kenya.

During public health crises, people living with HIV (PLWH) may become disengaged from care. The goal of this study was to understand the impact of the COVID-19 pandemic and recent flooding disasters on HIV care delivery in western Kenya. We conducted ten individual in-depth interviews with HIV providers across four health facilities. We used an iterative and integrated inductive and deductive data analysis approach to generate four themes. First, increased structural interruptions created exacerbating strain on health facilities. Second, there was increased physical and psychosocial burnout among providers. Third, patient uptake of services along the HIV continuum decreased, particularly among vulnerable patients. Finally, existing community-based programs and teleconsultations could be adapted to provide differentiated HIV care. Community-centric care programs, with an emphasis on overcoming the social, economic, and structural barriers will be crucial to ensure optimal care and limit the impact of public health disruptions on HIV care globally.

Survey of Drug Information Database Preferences among Staff from Selected British Columbia Health Authorities.

BACKGROUND: With the increasing use of electronic point-of-care resources, it is imperative to clearly understand what health professionals consider valuable when selecting a drug information database. A current analysis of the preferences of staff in selected British Columbia health authorities was deemed helpful for determining which electronic drug information database should be purchased. OBJECTIVES: To determine the factors that BC hospital pharmacists, nurses, and other health professionals value in an electronic drug information database and to better understand the general preferences of staff in choosing between the Lexicomp and Micromedex databases. METHODS: An electronic survey was created for data collection. The survey was open from August 10 to September 15, 2018, and again from November 11 to December 7, 2018. The survey link was sent by e-mail to staff in the following health authorities: Fraser Health, Providence Health Care, Provincial Health Services Authority, and Vancouver Coastal Health. Qualitative and quantitative methods were used to analyze the survey data. RESULTS: A total of 247 responses were received, of which 145 (58.7%) were complete. Completed surveys were received from 77 pharmacists, 52 nurses, and 16 other health professionals. Participants ranked dosing information and ease of use as the most important factors that they considered when choosing a drug information database. There were no significant differences between the Lexicomp and Micromedex resources in terms of usability, quality, and preference. CONCLUSIONS: This survey provided insights into what BC health authority staff perceive as important when utilizing a drug information database. Those considering either renewing or initiating a subscription to an online drug information database can use these results to better understand the preferences of health care professionals. Survey respondents ranked dosing information and ease of use as the 2 most important factors in selecting a drug information database. Pharmacists were more particular about using their preferred database than were other health professionals.

CONTEXTE: Avec l'utilisation croissante de ressources électroniques aux points de services, il est impératif de bien comprendre ce que les professionnels de la santé estiment important lorsqu'ils choisissent une base de données sur les médicaments. Une analyse actuelle des préférences des membres du personnel des autorités sanitaires sélectionnées de la Colombie-Britannique a été jugée utile pour déterminer le type de base de données sur les médicaments à acheter. OBJECTIFS: Déterminer quels facteurs sont importants pour les pharmaciens d'hôpitaux, les infirmiers et les autres professionnels de la santé de la C.-B. lors du choix d'une base de données électronique sur les médicaments et mieux cerner les préférences générales des membres du personnel lorsqu'ils choisissent entre les bases de données Lexicomp et Micromedex. MÉTHODES: Un sondage électronique a servi à la collecte des données. Il s'est déroulé du 10 août au 15 septembre 2018, et à nouveau du 11 novembre au 7 décembre 2018. Les membres du personnel des autorités sanitaires suivantes ont reçu le lien menant au sondage: Fraser Health, Providence Health Care, Provincial Health Services Authority et Vancouver Coastal Health. L'analyse des données a été effectuée à l'aide de méthodes qualitatives et quantitatives. RÉSULTATS: Les investigateurs ont reçu 247 réponses, dont 145 étaient complètes (58,7 %). Soixante-dix-sept (77) pharmaciens, 52 infirmiers et 16 autres professionnels de la santé ont dument rempli le sondage. Les participants ont indiqué que les renseignements sur le dosage et la facilité d'utilisation étaient les deux facteurs les plus importants à prendre en compte lors du choix d'une base de données sur les médicaments. Aucune différence significative n'est ressortie entre les bases de données Lexicomp et Micromedex quant à l'opérabilité, la qualité et la préférence. CONCLUSIONS: Ce sondage a permis de fournir un aperçu sur ce que les membres du personnel des autorités sanitaires de la C.-B. percevaient comme important pour l'utilisation d'une base de données sur les médicaments. Les personnes qui ont l'intention de renouveler ou de souscrire un abonnement à une base de données sur les médicaments en ligne peuvent utiliser ces résultats pour mieux cerner les préférences des professionnels de la santé. Les répondants ont indiqué que les renseignements sur le dosage et la facilité d'utilisation étaient les deux facteurs les plus importants à prendre en compte lors du choix d'une base de données sur les médicaments. Les pharmaciens étaient moins disposés que les autres professionnels de la santé à changer leur base de données préférée pour une autre.

Unique pharmacology of heteromeric α7ß2 nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes.

α7ß2 is a novel type of nicotinic acetylcholine receptor shown to be uniquely expressed in cholinergic neurons of the basal forebrain and in hippocampal interneurons. We have compared the pharmacological properties of recombinant homomeric α7 and heteromeric α7ß2 nicotinic acetylcholine receptors in order to reveal the pharmacological consequences of ß2 subunit incorporation into the pentamer. The non-selective agonist epibatidine did not distinguish α7ß2 from α7 nicotinic acetylcholine receptors, but three other non-selective agonists (nicotine, cytisine and varenicline) were less efficacious on α7ß2 than on α7. A more dramatic change in efficacy was seen with eight different selective α7 agonists. Because of their very low intrinsic efficacy, some compounds became very efficacious functional antagonists at α7ß2 receptors. Three α4ß2 nicotinic receptor selective agonists that were not active on α7, were also inactive on α7ß2, and dihydro-ß-erythroidine, an α4ß2 receptor-preferring antagonist, inhibited α7 and α7ß2 in a similar manner. These results reveal significant effects of ß2 incorporation in determining the relative efficacy of several non-selective and α7 selective agonists, and also show that incorporation of ß2 subunits does not cause a shift to a more "ß2-like" pharmacology of α7 nicotinic acetylcholine receptors.